

VotinNumber of shares present or represented at the meeting (including abstentions):	86,830,602
Number of issued shares:	151,626,107
Percentage of issued shares present or represented at the meeting:	57.27%

Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast	cast FOR	votes cast	cast		of shares
		FOR		AGAINST	AGAINST		present or
							represented
First	Presentation of the special report of the	n/a	n/a	n/a	n/a	n/a	86,830,602
Item	board of directors of the Company (as						
	required pursuant to Article 441-7 of the						
	Luxembourg law of 10 August 1915 on						
	commercial companies, as amended) on any						
	transaction, since the last general meeting of						
	the Company, in respect of which any of the						
	directors declared to have an interest						
	conflicting with that of the Company.						



Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast	cast FOR	votes cast	cast		of shares
		FOR		AGAINST	AGAINST		present or
							represented
Second	Presentation of the combined management	n/a	n/a	n/a	n/a	n/a	86,830,602
Item	report of the board of directors of the						
	Company in respect of the unaudited						
	standalone annual accounts of the Company						
	and the unaudited consolidated financial						
	statements of the Company and its group for						
	the financial year ending 31 December 2022.						
Third	Approval of the <u>unaudited</u> standalone annual	80,892.542	97.55%	2,035,738	2.45%	3,902,322	86,830,602
Item	accounts of the Company for the financial						
	year ending 31 December 2022.						



Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast	cast FOR	votes cast	cast		of shares
		FOR		AGAINST	AGAINST		present or
							represented
Fourth	Approval of the <u>unaudited</u> consolidated	80,892.542	97.55%	2,035,738	2.45%	3,902,322	86,830,602
Item	financial statements of the Company and its						
	group for the financial year ending 31						
	December 2022.						
Fifth	Approval of the allocation of the statutory	86,830,601	99.999999%	1	0.000001%	0	86,830,602
Item	financial results for the financial year ending						
	31 December 2022.						
Sixth	Approval of the granting of discharge (quitus)	80,892,607	93.16%	5,937,995	6.84%	0	86,830,602
Item	to all directors who held office during the						
	financial year ending 31 December 2021 in						
	respect of the performance of their duties						
	during that financial year.						



Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast	cast FOR	votes cast	cast		of shares
		FOR		AGAINST	AGAINST		present or
							represented
Seventh	Approval of the appointment of Mr. Thomas	86,830,602	100%	0	0%	0	86,830,602
Item	Josef Echelmeyer, as director of the						
	Company for a period running from the date						
	of this AGM until the annual general meeting						
	to take place in the year 2026.						
Eight	Approval of the appointment of Dr. Heiner	86,388,006	100%	0	0%	442,596	86,830,602
Item	Arnoldi, as director of the Company for a						
	period running from the date of this AGM until						
	the annual general meeting to take place in						
	the year 2026.						



Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast	cast FOR	votes cast	cast		of shares
		FOR		AGAINST	AGAINST		present or
							represented
Ninth	Approval of the appointment of Mr. Stefan	86,830,602	100%	0	0%	0	86,830,602
Item	Brendgen, as director of the Company for a						
	period running from the date of this AGM until						
	the annual general meeting to take place in						
	the year 2026.						
Tenth	Approval of the appointment of a new	80,642,542	97.56%	2,018,554	2.44 %	4,169,506	86,830,602
Item	approved statutory auditor / approved audit						
	firm of the Company until the annual general						
	meeting to take place in 2024.						
Eleventh	Approval (on an advisory and non-binding	73,915,734	92.57%	5,932,995	7.43%	6,981,873	86,830,602
Item	basis) of the remuneration policy of the						
	Company.						



Item	Subject Matter	Number of	% of votes	Number of	% of votes	Abstentions	Total numbers
		votes cast FOR	cast FOR	votes cast AGAINST	cast AGAINST		of shares
							present or
							represented
Twelfth	Approval (on an advisory and non-binding	74,165,734	92.59%	5,932,995	7.41%	6,731,873	86,830,602
Item	basis) of the remuneration report of the						
	Company for the financial year ending 31						
	December 2022.						